Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-07

Clinical Trial Update: Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating abatacept for hospitalized COVID-19 patients with respiratory compromise was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abatacept (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: COVID-19, SARS-CoV-2 | Phase 2 | Status: TERMINATED | Results posted: 2022-10-07